<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02029911</url>
  </required_header>
  <id_info>
    <org_study_id>CIP0003</org_study_id>
    <nct_id>NCT02029911</nct_id>
  </id_info>
  <brief_title>A Multi-Center, Single Arm Clinical Study of the Safety and Efficacy of the AURORA™ Endometrial Ablation System</brief_title>
  <official_title>A Multi-Center, Single Arm Clinical Study of the Safety and Efficacy of the AURORA™ Endometrial Ablation System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Minerva Surgical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Minerva Surgical, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, single-arm, non-randomized, prospective clinical study. The clinical
      study is designed as a non-inferiority study to assess the effectiveness of the Aurora
      Endometrial Ablation System compared to an objective standard. Safety will be evaluated by
      determining the number and percentage of subjects who experience one or more of serious
      adverse events.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in Menstrual Blood Loss to Normal Levels at 12 Months</measure>
    <time_frame>12 Months</time_frame>
    <description>Number of subjects in whom menstrual blood loss was reduced to normal or below normal levels at 12 months, as measured by a pictorial blood loss assessment chart (PBLAC) score of &lt;=75.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedure Time</measure>
    <time_frame>&lt; 1 hour</time_frame>
    <description>Procedure Time defined as time from insertion of the Disposable Handpiece to the time of removal.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Menorrhagia Due to Benign Causes</condition>
  <arm_group>
    <arm_group_label>Aurora Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endometrial Ablation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Aurora Endometrial Ablation System</intervention_name>
    <description>Ablation of the endometrial lining of the uterus using the Aurora System</description>
    <arm_group_label>Aurora Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Refractory menorrhagia with no definable organic cause

          2. Female subject from age 25 to 50 years

          3. Uterine sound measurement of 6.0cm to 10.0cm (external os to internal fundus)

          4. One of the following criteria:

             A. Documented history of menorrhagia secondary to dysfunctional uterine bleeding
             (DUB).

             B. If a pictorial blood loss assessment chart (PBLAC) scoring systems is used; a
             minimum PBLAC score of ≥150 for 1 month prior to study enrollment.

          5. Premenopausal at enrollment as determined by FSH measurement ≤ 40 IU/ml

          6. Not pregnant and no desire to be pregnant in the future

          7. Patient agrees not to use hormonal contraception or any other medical intervention for
             bleeding during the study

          8. Able to provide written informed consent using a form that has been approved by the
             reviewing IRB/EC

          9. Subject agrees to follow-up exams and data collection, including ability to accurately
             use menstrual diaries for PBLAC analysis.

         10. Subject who is literate or demonstrates an understanding on how to use menstrual
             diaries.

        Exclusion Criteria:

          1. Pregnancy or subject with a desire to conceive

          2. Endometrial hyperplasia as confirmed by histology

          3. Presence of active endometritis

          4. Active pelvic inflammatory disease

          5. Active sexually transmitted disease (STD), at the time of ablation. Note: Treatment of
             STD documented in the chart serves as sufficient evidence of infection resolution.
             Patient may be considered for study enrollment.

          6. Presence of bacteremia, sepsis, or other active systemic infection

          7. Active infection of the genitals, vagina, cervix, uterus or urinary tract at the time
             of the procedure

          8. Known/suspected gynecological malignancy within the past 5 years

          9. Known clotting defects or bleeding disorders

         10. Untreated/unevaluated cervical dysplasia (except CIN I)

         11. Known/suspected abdominal/pelvic cancer

         12. Prior uterine surgery (except low segment cesarean section) that interrupts the
             integrity of the uterine wall (e.g., myomectomy or classical cesarean section)

         13. Previous endometrial ablation procedure

         14. Currently on medications that could thin the myometrial muscle, such as long-term
             steroid use (except inhaler or nasal therapy for asthma)

         15. Currently on anticoagulants

         16. Abnormal or obstructed cavity as confirmed by hysteroscopy or SIS, specifically:

               1. Septate or bicornuate uterus or other congenital malformation of the uterine
                  cavity

               2. Pedunculated or submucosal myomas distorting the uterine cavity

               3. Polyps likely to be the cause of the subject's menorrhagia

               4. Intramural or subserosal myomas that distort the uterine cavity

         17. Presence of an intrauterine device (IUD) which the patient is unwilling to have
             removed at the time of the operative visit

         18. Presence of an implantable contraceptive device (e.g. Essure or Adiana).

         19. Subject currently on hormonal birth control therapy or unwilling to use a non-hormonal
             birth control post-ablation (including a Mirena device).

         20. Subject who is within 6-weeks post partum.

         21. Any general health condition which, in the opinion of the Investigator, could
             represent an increased risk for the subject

         22. Any subject who is currently participating or considers future participation in any
             other research of an investigational drug or device.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hôpital du Sacré-Coeur de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Lasalle</name>
      <address>
        <city>Ville Lassalle</city>
        <state>Quebec</state>
        <zip>H8P 1C1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>La Cite Medicale</name>
      <address>
        <city>Quebec</city>
        <zip>G1W 2J5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2014</study_first_submitted>
  <study_first_submitted_qc>January 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2014</study_first_posted>
  <results_first_submitted>August 27, 2015</results_first_submitted>
  <results_first_submitted_qc>October 6, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 5, 2015</results_first_posted>
  <disposition_first_submitted>August 20, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>August 20, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 22, 2014</disposition_first_posted>
  <last_update_submitted>October 6, 2015</last_update_submitted>
  <last_update_submitted_qc>October 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Menorrhagia</keyword>
  <keyword>Excessive uterine bleeding</keyword>
  <keyword>Endometrial Ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Menorrhagia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled in the clinical trial at 3 investigational sites in Canada from June 2011 until October 2011.</recruitment_details>
      <pre_assignment_details>63 subjects enrolled: 3 subjects excluded based on pre-procedure hysteroscopy screening and did not receive treatment. The remaining 60 subjects completed the study treatment. The protocol ITT population included all subjects in whom treatment was attempted (the experimental device was attempted to be placed).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Aurora Treatment Arm</title>
          <description>Endometrial Ablation
Aurora Endometrial Ablation System: Ablation of the endometrial lining of the uterus using the Aurora System</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60">Treatment Attempted</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="60">Treatment Completed</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60">Completed 12 Month Follow-up</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Subjects Treated</population>
      <group_list>
        <group group_id="B1">
          <title>Aurora Treatment Arm</title>
          <description>Endometrial Ablation
Aurora Endometrial Ablation System: Ablation of the endometrial lining of the uterus using the Aurora System</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.5" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PBLAC Score (assessment of menstrual blood loss)</title>
          <description>Pictorial Blood Loss Assessment Chart (PBLAC) is a tool used to assess menstrual blood loss. The PBLAC score takes into account the number of menstrual pads and tampons used as well as amount of saturation. A score of 0 represents no bleeding. Although the PBLAC score does not yield an exact measure of blood loss, it has been found to correlate well with menstrual blood volume. A score greater than 100 is correlated with a blood loss of at least 80 mL.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="503.0" spread="412.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Reduction in Menstrual Blood Loss to Normal Levels at 12 Months</title>
        <description>Number of subjects in whom menstrual blood loss was reduced to normal or below normal levels at 12 months, as measured by a pictorial blood loss assessment chart (PBLAC) score of &lt;=75.</description>
        <time_frame>12 Months</time_frame>
        <population>Protocol Intent-to-treat populations (all subjects in whom the experimental device was attempted to be placed)</population>
        <group_list>
          <group group_id="O1">
            <title>Aurora Treatment Arm</title>
            <description>Endometrial Ablation
Aurora Endometrial Ablation System: Ablation of the endometrial lining of the uterus using the Aurora System</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction in Menstrual Blood Loss to Normal Levels at 12 Months</title>
          <description>Number of subjects in whom menstrual blood loss was reduced to normal or below normal levels at 12 months, as measured by a pictorial blood loss assessment chart (PBLAC) score of &lt;=75.</description>
          <population>Protocol Intent-to-treat populations (all subjects in whom the experimental device was attempted to be placed)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Procedure Time</title>
        <description>Procedure Time defined as time from insertion of the Disposable Handpiece to the time of removal.</description>
        <time_frame>&lt; 1 hour</time_frame>
        <population>Subjects completing treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Aurora Treatment Arm</title>
            <description>Endometrial Ablation
Aurora Endometrial Ablation System: Ablation of the endometrial lining of the uterus using the Aurora System</description>
          </group>
        </group_list>
        <measure>
          <title>Procedure Time</title>
          <description>Procedure Time defined as time from insertion of the Disposable Handpiece to the time of removal.</description>
          <population>Subjects completing treatment</population>
          <units>Minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Subjects With Amenorrhea at 12 Months</title>
        <description>Amenorrhea at 12 Months- Number of subjects experiencing no menstrual bleeding</description>
        <time_frame>12 Months</time_frame>
        <population>Protocol Intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Aurora Treatment Arm</title>
            <description>Endometrial Ablation
Aurora Endometrial Ablation System: Ablation of the endometrial lining of the uterus using the Aurora System</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With Amenorrhea at 12 Months</title>
          <description>Amenorrhea at 12 Months- Number of subjects experiencing no menstrual bleeding</description>
          <population>Protocol Intent-to-treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <desc>All Adverse Events observed during the clinical study, regardless of relationship to the study device or procedure are reported below.</desc>
      <group_list>
        <group group_id="E1">
          <title>Aurora Treatment Arm</title>
          <description>Endometrial Ablation
Aurora Endometrial Ablation System: Ablation of the endometrial lining of the uterus using the Aurora System</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Nausea-more than 24 hrs post-treatment</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Constipaion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Dental Ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever more than 24 hrs post-treatment</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Annulus Rectal Condyloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Superficial Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>ecchymosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Vagal Reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pelvic Cramping (non-specific)</sub_title>
                <counts group_id="E1" events="57" subjects_affected="47" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Vaginal Discharge</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Vulvitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Unpleasant Vaginal Odor</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pruritus Vulvae</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Vaginal Burning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Abnormal Pap test- CINII</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Anesthesia Related</sub_title>
                <counts group_id="E1" events="19" subjects_affected="12" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Eugene Skalnyi, VP Medical Affairs</name_or_title>
      <organization>Minerva Surgical, Inc.</organization>
      <phone>(1) 650-284-3500</phone>
      <email>eugenes@minervasurgical.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

